NEW YORK (GenomeWeb) – Molecular diagnostics firm Diagnovus announced today a licensing agreement with Cincinnati Children's Hospital Medical Center to commercialize a gene expression assay for the diagnosis of eosinophilic esophagitis (EoE).

The Engauge GI-EoE test, developed by researchers at the hospital, is the first genomic assay for diagnosing and treating EoE, Diagnovus said, adding it differentiates the ailment from gastroesophageal reflux disease (GERD) or chronic esophagitis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.

Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.

In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.

Iceland has nearly eliminated Down syndrome from its population, CBS News reports.